| Wissenschaftl. Titel | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC) |
| Erkrankung |
Geschlechtsorgane:
Brustkrebs:
neoadjuvant
|
| Molekularer Marker |
Triple neg (HER2/ER/PR neg) |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 13.11.2015 Alexandra Lucaciu
geändert 24.08.2018 Student Studienregister